{"id":"NCT00152464","sponsor":"UCB Pharma SA","briefTitle":"Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)","officialTitle":"The Early Prevention of Asthma in Atopic Children (EPAAC™) Study. A Multi-country, Double Blind, Placebo (PLC) Controlled, Randomized, Parallel Group Trial: Evaluation of the Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for 18 Months in Preventing the Onset of Asthma in 12 to 24 Months Old Children Who Suffer From Atopic Dermatitis and Are Sensitized to Grass Pollen and / or House Dust Mite Allergens.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-03-20","primaryCompletion":"2006-03-15","completion":"2006-03-15","firstPosted":"2005-09-09","resultsPosted":"2019-01-22","lastUpdate":"2019-01-22"},"enrollment":514,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dermatitis, Atopic"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Levocetirizine","otherNames":["Xyzal"]}],"arms":[{"label":"Levocetirizine (LCTZ)","type":"EXPERIMENTAL"},{"label":"Placebo (PBO)","type":"PLACEBO_COMPARATOR"}],"summary":"The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.","primaryOutcome":{"measure":"Time to Onset of Asthma During the Treatment Period","timeFrame":"During the treatment period (18 months)","effectByArm":[{"arm":"Placebo (PBO)","deltaMin":null,"sd":null},{"arm":"Levocetirizine (LCTZ)","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.991"}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":255},"commonTop":["Upper respiratory tract infection","Pyrexia","Nasopharyngitis","Rhinitis","Cough"]}}